Neos Therapeutics (NEOS) 10-K2018 FY Annual report

Filed: 18 Mar 19, 8:33am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Additionaly, Adhansia, Adlon, ALS, amyotrophic, Anatomic, antagonist, anticholinergic, appeal, argued, arithmetic, Bid, burden, Cap, cerebral, chapping, chronic, Circuit, concession, correspondingly, corridor, covertly, deadline, dehydration, diversify, drooling, excessive, explained, fifteen, fluid, foul, furlough, GDPR, Gerald, greatly, harbor, HCl, hereof, HHS, infection, inseverable, Inspector, Ironshore, Jornay, KemPharm, leadership, logistic, main, McLaughlin, mental, metabolite, micro, microparticle, molecule, month, motion, muscarinic, negligible, NeuRx, Northern, NRX, odor, OIG, ompany, oppose, Osomotica, overtly, oxybutynin, PA, palsy, parent, perioral, permission, Pharma, PM, pocket, pre, prolonged, psychosocial, Purdue, realigned, realignment, recasting, receptor, retardation, retention, ROU, salivation, shut, shutdown, sialorrhea, slight, ST, step, stigmatization, stranded, Takeda, therapy, timeframe, unclear, undertaken, upfront, urological, Vermont, worldwide, wrote

Removed: accrual, assured, Australia, collectability, destruction, determinable, dozen, exchanged, lab, neurology, psychiatry, resale, theft, vault

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated NEOS transcripts

NEOS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

QuickLinks -- Click here to rapidly navigate through this document

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-228748, No. 333-219108 and No. 333-212809) and Form S-8 (No. 333-226044, No. 333-223696, No. 333-216698, No. 333-210267 and No. 333-205937) of Neos Therapeutics, Inc. of our report dated March 18, 2019, relating to the consolidated financial statements and the financial statement schedule of Neos Therapeutics, Inc. appearing in this Annual Report on Form 10-K of Neos Therapeutics, Inc. for the year ended December 31, 2018.

/s/ RSM US LLP
Dallas, Texas
March 18, 2019

QuickLinks

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm